PUBLISHER: The Business Research Company | PRODUCT CODE: 1957400
PUBLISHER: The Business Research Company | PRODUCT CODE: 1957400
Machine learning (ML) in the pharmaceutical industry refers to the application of artificial intelligence (AI) algorithms and techniques to enhance various aspects of drug discovery, development, and manufacturing. Implementing ML solutions in the pharmaceutical sector requires careful adherence to regulatory standards and addressing potential challenges related to data quality, research gaps, and regulatory uncertainty.
The main components of machine learning (ML) in the pharmaceutical industry are solutions and services. Solutions refer to applications or systems that utilize machine learning algorithms and techniques to tackle specific challenges or tasks within the pharmaceutical field. These solutions can be deployed on cloud or on-premise platforms and are designed for enterprises of various sizes, including small and medium-sized enterprises (SMEs) as well as large enterprises.
Tariffs have affected the machine learning in the pharmaceutical industry market by increasing the cost of importing advanced computational hardware, cloud infrastructure, and specialized lab equipment. This has impacted segments such as predictive analytics tools and clinical trial optimization solutions, particularly in regions like North America and Europe that rely on imported AI technologies. While the tariffs have raised operational costs and slowed adoption in some cases, they have also encouraged local manufacturing and sourcing of AI hardware, fostering regional innovation and cost-efficient solutions.
The machine learning (ml) in the pharmaceutical industry market research report is one of a series of new reports from The Business Research Company that provides machine learning (ml) in the pharmaceutical industry market statistics, including machine learning (ml) in the pharmaceutical industry industry global market size, regional shares, competitors with a machine learning (ml) in the pharmaceutical industry market share, detailed machine learning (ml) in the pharmaceutical industry market segments, market trends and opportunities, and any further data you may need to thrive in the machine learning (ml) in the pharmaceutical industry industry. This machine learning (ml) in the pharmaceutical industry market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The machine learning (ml) in the pharmaceutical industry market size has grown exponentially in recent years. It will grow from $4.08 billion in 2025 to $5.52 billion in 2026 at a compound annual growth rate (CAGR) of 35.4%. The growth in the historic period can be attributed to increasing r&d investment in pharma, adoption of ai and ml in drug discovery, rising prevalence of chronic diseases, advancement in computational biology, collaboration between pharma and tech companies.
The machine learning (ml) in the pharmaceutical industry market size is expected to see exponential growth in the next few years. It will grow to $18.71 billion in 2030 at a compound annual growth rate (CAGR) of 35.7%. The growth in the forecast period can be attributed to growing integration of ai in clinical trials, expansion of precision medicine, increasing use of real-world data analytics, advancement in cloud-based pharmaceutical platforms, development of personalized therapeutics. Major trends in the forecast period include predictive drug discovery models, clinical trial optimization, real-world evidence data utilization, personalized medicine implementation, regulatory compliance automation.
The growing adoption of artificial intelligence (AI) is driving the use of machine learning (ML) in the pharmaceutical industry. AI refers to computer software that imitates human cognition to perform complex tasks such as analyzing, reasoning, and learning, while ML, a subset of AI, employs algorithms trained on data to create models capable of executing sophisticated tasks. AI and ML have been applied in pharmaceutical technology and drug delivery design, providing faster solutions to complex challenges. These technologies have the potential to transform drug delivery processes, enhance decision-making tools, and manage large volumes of data to enable more effective decisions. For instance, in June 2023, Forbes, a US-based business magazine, reported that approximately 432,000 UK organizations-about one in six-had adopted at least one AI technology. Adoption rates included 68% of large businesses, 33% of medium-sized businesses, and 15% of small businesses. Therefore, the increasing adoption of artificial intelligence (AI) is driving the growth of machine learning (ML) in the pharmaceutical industry.
Major companies operating in machine learning (ML) in the pharmaceutical industry are focusing on developing user-friendly software platforms, such as drug discovery software, to enhance their drug discovery capabilities. Drug discovery software encompasses a variety of specialized tools and platforms used throughout the process of identifying and developing new pharmaceutical drugs. For instance, in December 2023, Merck & Co. Inc., a US-based pharmaceutical company, launched the AIDDISON drug discovery software, the first software-as-a-service platform integrating drug discovery and synthesis using generative AI, machine learning, and computer-aided drug design. This platform allows laboratories to identify suitable drug candidates across a vast chemical space, virtually screen compounds from over 60 billion chemical targets, and evaluate synthesis routes for safer, more cost-effective, and higher-yield drug production.
In July 2023, BioNTech SE, a Germany-based biopharmaceutical company, acquired InstaDeep for $541 million. The acquisition is expected to reinforce BioNTech's leadership in AI-powered drug discovery, design, and development. InstaDeep, a UK-based technology company, provides a range of AI solutions and machine learning services for the pharmaceutical industry.
Major companies operating in the machine learning (ml) in the pharmaceutical industry market are Amazon.com Inc., Alphabet Inc., Microsoft Corporation, Dell Technologies Inc., Hitachi Ltd., International Business Machines Corporation, Cisco Systems Inc., Oracle Corporation, Honeywell International Inc., Hewlett Packard Enterprise, NVIDIA Corporation, Thales SA, Atos SE, Hexagon AB, Palantir Technologies Inc., Alteryx Inc., Comet ML Inc., GAVS Technologies, NEC Corporation, Veritone Inc., H2O.ai Inc., Sparkcognition Inc., Akira AI, Deep Genomics Inc., Cloud Pharmaceuticals Inc., Atomwise Inc., Cyclica Inc., BioSymetrics Inc., Neptune Labs
North America was the largest region in the machine learning in the pharmaceutical industry market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the machine learning (ml) in the pharmaceutical industry market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the machine learning (ml) in the pharmaceutical industry market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The machine learning (ML) in the pharmaceutical industry market consists of revenues earned by entities by providing components of machine learning (ML) in the pharmaceutical industry market such as solutions and services. The market value includes the value of related goods sold by the service provider or included within the service offering. The machine learning (ML) in the pharmaceutical industry market also includes sales of central processing units (CPUs), random access memory, storage systems, and graphics processing units (GPUs). Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Machine Learning (ML) in The Pharmaceutical Industry Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses machine learning (ml) in the pharmaceutical industry market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for machine learning (ml) in the pharmaceutical industry ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The machine learning (ml) in the pharmaceutical industry market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.